all

This Expert Clinical Review highlights the importance of a collaborative approach to the management of dyslipidemia and other cardiometabolic risk factors, including improved diagnosis and treatment, enhanced access to facilitation of lifestyle interventions, the optimization of pharmacotherapy, and patient education and empowerment.

The National Lipid Association (NLA) has released a comprehensive clinical review titled “Familial Chylomicronemia Syndrome: An Expert Clinical Review from the National Lipid Association.” This new guidance provides an in-depth examination of the diagnosis, management, and treatment landscape for familial chylomicronemia syndrome (FCS) — a rare and severe genetic disorder characterized by extremely high triglyceride levels (≥ 1,000 mg/dL) and an elevated risk of life-threatening recurrent acute pancreatitis.